IOP lowering

Opportunities and challenges in the world of ophthalmology in 2018As another year comes to an end, five members of Ophthalmology Times Europe’s Editorial Advisory Board reflect and share their perspectives on the exciting opportunities that lie ahead for ophthalmologists in 2018, whilst also considering the potential challenges.
Applying micropulse transscleral cyclophotocoagulation for early-stage glaucoma Micropulse transscleral cyclophotocoagulation utilises a different delivery modality than its predecessor, continuous-wave laser cycloablation, to produce a biological reaction without the lethal effects caused by thermal buildup.
IOP fluctuations important factor in setting patients’ target pressureWhen setting a target IOP for patients with glaucoma, consideration of IOP fluctuations and the degree to which they vary is important.
Exploring safety, efficacy of high-intensity focused ultrasound in glaucomaHigh-intensity focused ultrasound cyclocoagulation is safe and effective in most refractory glaucomatous eyes. Complete success was achieved in 80% (24/30) of treated eyes that had undergone the maximum of three procedures.
Tracking treatment adherence in newly diagnosed open-angle glaucoma
Tracking treatment adherence in newly diagnosed open-angle glaucomaAn analysis of U.S. claims data reveals a substantial proportion of patients (17%) remained untreated 4 years after their initial diagnosis of open-angle glaucoma.
European study with microstent demonstrates lowered IOP, use of fewer drugsPatients with cataract surgery and microstent implantation had a lowered IOP and a reduced number of medications used at 3 years postoperatively
Novel ocular hypotensive drug meets endpointsNetarsudil ophthalmic solution 0.02% met its primary and secondary efficacy endpoints in a third phase III trial investigating its non-inferiority to timolol maleate 0.05% for IOP lowering.
Addressing ocular surface toxicity in glaucoma patientsDry eye is common in patients with glaucoma and often presumed to be related to the preservative in IOP-lowering medications. Considering alternate causes should also be weighed, in addition to a variety of management techniques.
Novel dual agonist leads to notable IOP loweringThe drug ONO-9054 led to a greater reduction in IOP and a longer duration of reduction in a small clinical trial compared with latanoprost.
Laser therapy addresses bilateral glaucoma in single treatmentLaser therapy that approaches bilateral glaucoma in a single treatment provides greater efficacy for the practice and more convenience for patients.